Tratamiento de hepatitis C crónica en pacientes con enfermedad renal: aportes a la Guía de Práctica Clínica del Seguro Social de Salud del Perú (EsSalud)

Zamora, Jose Armando Gonzales; Ponce-Rosas, Linda; Alave, Jorge

doi:10.47892/rgp.2022.422.1360

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Follow-up should be planned at 2 days following the initiation of treatment; failure of clinical response at that time or clinical progression should lead to a stool culture and change in antibiotic. Despite this being the formal national recommendation, expert national practitioners have advocated for alternative management based on available evidence of resistance to recommended first-line therapies of ciprofloxacin (10–15 mg/kg/dose every 12 hours for 5 days) and azithromycin (10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2–5) as first- and second-line oral options with ceftriaxone (50–75 mg/kg/day) indicated in cases where parenteral therapy is indicated [ 32 ]. This is challenged by the fact that public health establishments will only be reimbursed for pharmaceuticals that are specified under the national guidelines.…”

Section: Summary Of Diarrhea Management Guidelinesmentioning

confidence: 99%

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Peru

Manzanares Villanueva,

Pinedo Vasquez,

Peñataro Yori

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The Enterics for Global Health (EFGH) Peru site will enroll subjects in a periurban area of the low Amazon rainforest. The political department of Loreto lags behind most of Peru in access to improved sources of water and sanitation, per capita income, children born <2.5 kg, and infant and child mortality. Chronic undernutrition as manifested by linear growth shortfalls is common, but wasting and acute malnutrition are not. Methods The recruitment of children seeking care for acute diarrheal disease takes place at a geographic cluster of government-based primary care centers in an area where most residents are beneficiaries of free primary healthcare. Results Rates of diarrheal disease, dysentery, and Shigella are known to be high in the region, with some of the highest rates of disease documented in the literature and little evidence in improvement over the last 2 decades. This study will update estimates of shigellosis by measuring the prevalence of Shigella by polymerase chain reaction and culture in children seeking care and deriving population-based estimates by measuring healthcare seeking at the community level. Conclusions Immunization has been offered universally against rotavirus in the region since 2009, and in a context where adequate water and sanitation are unlikely to obtain high standards in the near future, control of principal enteropathogens through immunization may be the most feasible way to decrease the high burden of disease in the area in the near future.

show abstract

Section: Summary Of Diarrhea Management Guidelinesmentioning

confidence: 99%

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Peru

Manzanares Villanueva,

Pinedo Vasquez,

Peñataro Yori

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review

Gonzales-Zamora,

Quispe-Vicuña,

Reategui-Garcia

et al. 2024

JCM

View full text Add to dashboard Cite

Hepatitis C virus still represents a major cause of morbidity and mortality worldwide. In Peru, two national practice guidelines for the management of this infection were published more than 5 years ago; however, the latest breakthroughs in the treatment make it necessary to update these guidelines. We reviewed the most recent recommendations of the international guidelines and compared them with the current Peruvian guidelines. We found major differences, such as the use of Glecaprevir/Pibrentasvir as a first-line therapy, which is contemplated in the World Health Organization guideline, and recommended by American and European guidelines, but is not considered in the Peruvian guidelines. Another crucial difference lies in the management of patients with chronic kidney disease, who are treated nowadays with a variety of direct-acting antivirals, with no restrictions on the use of Sofosbuvir-based regimens in first-world countries, an approach that has not been adopted in Peru. We believe that standardization of the recommendations of the Peruvian guidelines is imperative, including the new therapeutic strategies that have emerged in recent years. We also suggest conducting a cost effectiveness analysis in the Peruvian context to allow for the implementation of new antivirals, and to achieve a better control of hepatitis C in the country.

show abstract

Tratamiento de hepatitis C crónica en pacientes con enfermedad renal: aportes a la Guía de Práctica Clínica del Seguro Social de Salud del Perú (EsSalud)

Abstract: -

Cited by 2 publications

References 0 publications

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Peru

The Enterics for Global Health (EFGH) Shigella Surveillance Study in Peru

Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review

Contact Info

Product

Resources

About